MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ataxia: Treatment"

  • 2019 International Congress

    Think of Gluten Ataxia:A rare but potentially reversible cause of progressive neurological disorder

    R. Mathur, K. Lal, A. Kyi (Grantham, United Kingdom)

    Objective: To explore an unusual cause of ataxia in a patient with known Celiac disease. Background: Celiac disease is the established but not the only…
  • 2019 International Congress

    A case of cerebellar ataxia caused by Pembrolizumab for Non-small cell lung cancer

    T. Moto, H. Nagayama, K. Kimura (Tokyo, Japan)

    Objective: We reported a case that cerebellar ataxia and decreased accumulation of right cerebellum at SPECT appeared after immunotherapy using immune-checkpoint inhibitor “Pembrolizumab” for Non-small…
  • 2019 International Congress

    Inpatient vs outpatient workup of patients with ataxia and suspected paraneoplastic cerebellar degeneration: Does work-up location matter?

    N. Witek, M. Afshari, Y. Liu, B. Ouyang, D. Hall (Chicago, IL, USA)

    Objective: To assess the outcomes of patients with ataxia evaluated for paraneoplastic syndrome primarily in an outpatient or inpatient setting. Background: Although paraneoplastic ataxias are…
  • 2018 International Congress

    Respiratory Complaints in Individuals with Spinocerebelar Ataxia Type 2

    N. Mello, H. Teive (Curitiba, Brazil)

    Objective: Verify the presence of respiratory complaints and dysfunction in individuals with spinocerebellar ataxia type 2 (SCA2).SCA2 is characterized by cerebellar ataxia, accompanied by dysarthria,…
  • 2018 International Congress

    Cerebello-spinal stimulation in neurodegenerative ataxia: A randomized, double-blind, sham-controlled, crossover trial

    A. Benussi, V. Dell'Era, V. Cantoni, E. Bonetta, R. Grasso, R. Manenti, M. Cotelli, A. Padovani, B. Borroni (Brescia, Italy)

    Objective: The present study investigated whether a two-weeks' treatment with cerebellar anodal and spinal cathodal transcranial direct current stimulation (tDCS) could reduce symptoms in patients…
  • 2018 International Congress

    Cerebellar Ataxia as a Manifestation of Hashimoto Encephalopathy

    S. Thakolwiboon, D. Ruthirago, V. Senanarong (Lubbock, TX, USA)

    Objective: To characterize the clinical, laboratory and radiologic findings as well as prognosis of Hashimoto encephalopathy (HE) presenting with cerebellar ataxia Background: HE is a…
  • 2018 International Congress

    Dissociative effects of thyrotropin releasing hormone on classical cerebellar ataxic signs and cerebellar adaptation in patients with spinocerebellar degeneration

    T. Shimizu, R. Hanajima, R. Tsutsumi, N. Tominaga, Y. Ugawa, K. Nishiyama (Sagamihara, Japan)

    Objective: To reveal effects of TRH [Thyrotropin releasing hormone (protirelin tartrate)] on the prism adaptation task in patients with spinocerebellar degeneration (SCD). Background: The cerebellum…
  • 2018 International Congress

    Treatment with docosahexaenoic acid in Spinocerebellar Ataxia 38

    D. Perani, L. Orsi, C. Costanzi, M. Ferrero, A. Zoppo, F. Tempia, D. Caruso, M. Grassi, A. Padovani, A. Brusco, B. Borroni (Brescia, Italy)

    Objective: To evaluate the safety and efficacy of docosahexaenoic acid supplementation in patients with spinocerebellar ataxia 38 (SCA 38), on clinical symptoms and changes of…
  • 2017 International Congress

    Targeting the intracellular localization of Ataxin-3 as novel treatment strategy for Spinocerebellar Ataxia Type 3

    T. Schmidt, Z. Wang, A. Sowa, J. Schmidt, M. Anders, M.I. Martins, A. de Castro, D. Weishäupl, J. Weber, H. Tricoire, P. Maciel, O. Riess (Tuebingen, Germany)

    Objective: Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is an autosomal-dominantly inherited neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene…
  • 2017 International Congress

    Is the cerebellum a good target for neuromodulation in movement disorders?

    C. França, M. Teixeira, D. de Andrade, R. Galhardoni, V. Barbosa, V. Silva, G. Lepski, E. Barbosa, R. Cury (São Paulo, Brazil)

    Objective: To assess the effects of dentate nucleus transcranial magnetic stimulation and deep brain stimulation on patients with cerebellar ataxia of different etiologies. Background: Cerebellar…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley